Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AML

Video

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).

As with all agents being explored in AML, there is interest in using FLT3 inhibitors in combination with chemotherapy, though discussion remains regarding sequencing. Faderl says he believes there is interest in both moving away from intensive chemotherapy for the treatment of AML and combining FLT3 inhibitors with lower-intensity therapies.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD